Onconetix (ONCO) Competitors $0.08 0.00 (-1.93%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. NAII, CGTX, DRRX, ELEV, BIVI, CMMB, LPCN, JATT, MTEX, and NRSNShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Natural Alternatives International (NAII), Cognition Therapeutics (CGTX), DURECT (DRRX), Elevation Oncology (ELEV), BioVie (BIVI), Chemomab Therapeutics (CMMB), Lipocine (LPCN), JATT Acquisition (JATT), Mannatech (MTEX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Natural Alternatives International Cognition Therapeutics DURECT Elevation Oncology BioVie Chemomab Therapeutics Lipocine JATT Acquisition Mannatech NeuroSense Therapeutics Onconetix (NASDAQ:ONCO) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do insiders & institutionals have more ownership in ONCO or NAII? 23.9% of Onconetix shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 3.1% of Onconetix shares are owned by insiders. Comparatively, 20.9% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor ONCO or NAII? In the previous week, Natural Alternatives International had 2 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Natural Alternatives International and 1 mentions for Onconetix. Natural Alternatives International's average media sentiment score of 0.28 beat Onconetix's score of 0.00 indicating that Natural Alternatives International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Natural Alternatives International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ONCO or NAII more profitable? Natural Alternatives International has a net margin of -6.26% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat Natural Alternatives International's return on equity.Company Net Margins Return on Equity Return on Assets Onconetix-2,758.89% N/A -48.09% Natural Alternatives International -6.26%-9.36%-4.82% Which has higher valuation & earnings, ONCO or NAII? Natural Alternatives International has higher revenue and earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$1.87M2.81-$37.41MN/AN/ANatural Alternatives International$125.48M0.16-$7.22M-$1.39-2.39 Does the MarketBeat Community prefer ONCO or NAII? Natural Alternatives International received 279 more outperform votes than Onconetix when rated by MarketBeat users. CompanyUnderperformOutperformOnconetixN/AN/ANatural Alternatives InternationalOutperform Votes27977.07% Underperform Votes8322.93% Which has more volatility & risk, ONCO or NAII? Onconetix has a beta of 3.49, suggesting that its stock price is 249% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. SummaryNatural Alternatives International beats Onconetix on 9 of the 12 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.22M$6.51B$5.35B$8.44BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1526.9119.77Price / Sales2.81259.30390.06119.10Price / CashN/A65.8538.2534.62Price / Book0.036.476.794.52Net Income-$37.41M$144.21M$3.23B$248.23M7 Day PerformanceN/A2.64%1.99%0.77%1 Month PerformanceN/A4.80%11.45%13.45%1 Year PerformanceN/A-2.52%17.35%7.67% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.0635 of 5 stars$0.08-1.9%N/A-98.4%$5.22M$1.87M0.0012News CoverageGap DownNAIINatural Alternatives International0.7338 of 5 stars$3.31+1.8%N/A-49.7%$20.52M$121.85M-2.57290News CoverageAnalyst ForecastGap UpCGTXCognition Therapeutics2.5526 of 5 stars$0.33+1.5%$6.13+1,756.1%-86.0%$20.46MN/A-0.3420Gap UpDRRXDURECT0.1829 of 5 stars$0.65+3.1%N/A-54.4%$20.17M$2.03M-1.0780Analyst ForecastGap DownHigh Trading VolumeELEVElevation Oncology2.9158 of 5 stars$0.34+20.4%$3.39+895.8%-91.5%$20.14MN/A-0.4140Negative NewsEarnings ReportBIVIBioVie2.706 of 5 stars$1.07+3.9%$3.00+180.4%+106.7%$19.86MN/A-0.1110Gap UpCMMBChemomab Therapeutics3.3109 of 5 stars$1.39+1.5%$8.50+511.5%+68.3%$19.67MN/A-1.3920Earnings ReportLPCNLipocine1.542 of 5 stars$3.63-9.0%$10.00+175.5%-44.6%$19.42M$3.67M-4.7810News CoverageGap UpJATTJATT AcquisitionN/A$1.11-7.5%N/A-82.1%$19.15MN/A0.003High Trading VolumeMTEXMannatech0.4988 of 5 stars$9.93-5.9%N/A+34.0%$18.88M$117.87M-12.26250News CoverageAnalyst ForecastGap DownNRSNNeuroSense Therapeutics2.4467 of 5 stars$1.37+3.8%$14.00+921.9%+19.0%$18.72MN/A-2.1410Gap Up Related Companies and Tools Related Companies NAII Alternatives CGTX Alternatives DRRX Alternatives ELEV Alternatives BIVI Alternatives CMMB Alternatives LPCN Alternatives JATT Alternatives MTEX Alternatives NRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCO Stock Free ONCO Stock Alerts